On November 27, the Plenary Meeting of the Executive Committee of the 12th Chinese Pharmacopoeia Commission (ChPC) was held in Beijing to review and approve the Draft of Pharmacopoeia of the People’s Republic of China 2025 Edition, and to deploy efforts to promote the publication and implementation of the new version of the Pharmacopoeia. Li Li, Secretary of the Party Group, Commissioner of the National Medical Products Administration (NMPA), and Chairman of the 12th ChPC, attended the meeting and delivered a speech. Wang Zhiyong, Party member, Deputy Commissioner of the National Administration of Traditional Chinese Medicine (NATCM), and Vice Chairman of the 12th ChPC, briefed on the deliberation of the 2025 edition of the Pharmacopoeia; Zhao Junning, Party member, Deputy Commissioner of the NMPA, and Vice Chairman of the 12th ChPC, announced the adjusted list of members of the Executive Committee of the 12th ChPC; and Huang Guo, Party member, Deputy Commissioner of the NMPA, and Vice Chairman of the 12th ChPC, presided over the meeting.

　　Li pointed out that drug standards are the benchmark for drug quality and safety, and the Pharmacopoeia is the core of the national drug standard system. With the joint efforts of all members, the compilation of the 2025 edition of the Pharmacopoeia paid more attention to incorporating innovative achievements, improving the structure and style, strictly abiding by the safety bottom line and standardizing the compilation procedure. The scientificity, systematicity, safety, and standardization of the Pharmacopoeia have been significantly improved, forming a comprehensive drug standard system covering Chinese medicinal materials, prepared slices of Chinese crude drugs, traditional Chinese medicines, chemical drugs, biological products, pharmaceutical excipients, pharmaceutical packaging materials and other categories. The goals and tasks of the preparation of the outline have been successfully completed.

　　Li emphasized that the publication and implementation of the new version of the Pharmacopoeia will build a stronger "wall of protection" for the safety of the public medication, provide a clearer "compass" for the promotion of high-quality development of the pharmaceutical industry, and build a more convenient "new bridge" for Chinese medicines to go global. He stressed that we should resolutely implement the Four Strictest requirements of General Secretary Xi Jinping, coordinate to ensure a high level of safety of drugs and promote the high-quality development of the pharmaceutical industry, and work hard to create a new situation for drug standards. Firstly, we should actively promote the construction of drug standard system and management capacity, carry out in-depth scientific research on drug standards, strengthen the construction of drug standard talents, and improve the level of performance of pharmacopoeia members. Secondly, we should comprehensively improve the overall level of national drug standards, perfect the dynamic management mechanism for standard improvement, and enhance the international recognition and influence of Chinese drug standards. Thirdly, we should do a good job in publishing and implementing the new version of the Pharmacopoeia, strengthen publicity and training and policy interpretation, and give better play to the fundamental and guiding role of drug standards in strengthening high-efficiency regulation, guaranteeing a high level of safety, and promoting high-quality development.

　　Members of the Executive Committee of the 12th ChPC, and officials in charge of relevant departments as well as directly affiliated institutions of NMPA participated in the meeting.

　　(From: National Medical Products Administration website 2024-11-27)